{"id":"NCT00003702","sponsor":"Gynecologic Oncology Group","briefTitle":"Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia","officialTitle":"A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus \"Pulsed\" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1999-06","primaryCompletion":"2010-07","completion":null,"firstPosted":"2003-01-27","resultsPosted":"2018-05-15","lastUpdate":"2018-05-15"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Good Prognosis Metastatic Gestational Trophoblastic Tumor","Hydatidiform Mole","Non-Metastatic Gestational Trophoblastic Tumor","Uterine Corpus Choriocarcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Dactinomycin","otherNames":["Actinomycin A IV","Actinomycin C1","ACTINOMYCIN D","Actinomycin I1","Actinomycin IV","Actinomycin X 1","Actinomycin-[thr-val-pro-sar-meval]","Cosmegen","DACT","Dactinomycine","Lyovac Cosmegen","Meractinomycin"]},{"type":"DRUG","name":"Methotrexate","otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]}],"arms":[{"label":"Arm I (methotrexate)","type":"EXPERIMENTAL"},{"label":"Arm II (dactinomycin)","type":"EXPERIMENTAL"}],"summary":"Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.","primaryOutcome":{"measure":"Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay","timeFrame":"Endpoint was assessed by hCG measurements taken weekly, once normal, treatment was bi-weekly, then monthly, up to 12 months.","effectByArm":[{"arm":"Arm 1: Methotrexate 30 mg/m2 IM Weekly","deltaMin":57,"sd":null},{"arm":"Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks","deltaMin":76,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":false,"inclusionCount":20,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["Nausea","Constitutional","Pain","Neutropenia","Hemorrhage"]}}